Ticker Hub
VYGR — AI Analysis & Sentiment
12 recent AI-generated analyses for VYGR. Sentiment and confidence insights updated continuously.
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
Voyager Therapeutics' FDA IND clearance for its Alzheimer's gene therapy VY1706 represents a significant de-risking event for its lead pipeline can...
Jun 1, 2026Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager's VY1706 for Alzheimer's showed strong preclinical safety and efficacy, paving the way for human trials. This positive data enhances the pr...
May 13, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager's extended cash runway into 2028 significantly de-risks the company's financial profile, providing critical stability for its clinical pipe...
Mar 9, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics reported strong Q4 results and extended its cash runway into 2028, significantly reducing near-term financial risk. This provi...
Mar 9, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics reported Q4 2025 financial results and significantly extended its cash runway into 2028. This greatly reduces financial risk a...
Mar 9, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics' extended cash runway into 2028 and improved Q4 2025 financials significantly de-risk the company. This provides a stable foun...
Mar 9, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics is making strong progress in its clinical pipeline, backed by an extended cash runway into 2028, positioning it for potential ...
Mar 9, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics reported strong Q4 2025 results and, crucially, extended its cash runway into 2028, significantly reducing financial risk. Thi...
Mar 9, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager reported improved Q4 and full year 2025 financial results. The company significantly reduced its quarterly net loss and, critically, extend...
Mar 9, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics has significantly reduced its financial risk by extending its cash runway into 2028 while reporting improved Q4 financials and...
Mar 9, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics reported strong Q4 results and a significantly extended cash runway into 2028, substantially reducing financial risk. This, co...
Mar 9, 2026Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics has extended its cash runway into 2028, substantially de-risking its operations. This financial stability, combined with clear...
Mar 9, 2026